World Investment Advisors LLC Takes $60,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

World Investment Advisors LLC bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 60,472 shares of the medical equipment provider's stock, valued at approximately $60,000. World Investment Advisors LLC owned 0.09% of Lantheus at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Hohimer Wealth Management LLC bought a new stake in shares of Lantheus in the 3rd quarter valued at $250,000. Coldstream Capital Management Inc. bought a new position in shares of Lantheus during the 3rd quarter valued at about $230,000. Geode Capital Management LLC grew its position in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after purchasing an additional 32,551 shares during the period. M&T Bank Corp grew its position in shares of Lantheus by 40.4% in the 3rd quarter. M&T Bank Corp now owns 6,847 shares of the medical equipment provider's stock valued at $752,000 after purchasing an additional 1,969 shares during the period. Finally, Groupama Asset Managment bought a new stake in Lantheus during the 3rd quarter worth approximately $439,000. 99.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. JMP Securities cut their price target on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday. They set a "buy" rating and a $143.00 target price for the company. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target on the stock. Finally, Truist Financial reiterated a "buy" rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Lantheus has a consensus rating of "Moderate Buy" and an average target price of $131.86.

Lantheus Trading Down 2.9 %

Shares of NASDAQ LNTH traded down $2.65 during mid-day trading on Friday, hitting $89.29. The company had a trading volume of 2,166,501 shares, compared to its average volume of 1,019,253. The firm has a 50-day simple moving average of $96.63 and a two-hundred day simple moving average of $98.18. The company has a market capitalization of $6.21 billion, a PE ratio of 14.86 and a beta of 0.45. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.